Company profile for Skye Bioscience

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We support a collaborative environment and know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed. Skye Bioscience (OTC: SKYE) is a biopharmaceutical company engineering proprietary cannabinoid derivatives to treat glaucoma and other diseases with significant unmet medical needs. Passion is at the heart of our company and drives every initiative. It is through our...
We support a collaborative environment and know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed. Skye Bioscience (OTC: SKYE) is a biopharmaceutical company engineering proprietary cannabinoid derivatives to treat glaucoma and other diseases with significant unmet medical needs. Passion is at the heart of our company and drives every initiative. It is through our passion that we have fostered a unique relationship between business, medicine, and people; one that is personal and authentic.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5910 Pacific Center Blvd, Suite 320 San Diego, CA 92121
Telephone
Telephone
(858) 410-0266
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/halozyme-and-skye-bioscience-announce-global-collaboration-and-license-agreement-to-evaluate-nimacimab-co-formulated-with-enhanze-for-obesity-302652323.html

PR NEWSWIRE
05 Jan 2026

https://www.globenewswire.com/news-release/2025/11/10/3185022/0/en/Skye-Bioscience-Reports-Third-Quarter-2025-Financial-Results-and-Business-Update.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181324/0/en/Skye-Bioscience-Late-Breaking-Oral-Abstract-at-ObesityWeek-2025-to-Highlight-Improvement-in-Rebound-Weight-Gain.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181276/0/en/Skye-Bioscience-to-Announce-Third-Quarter-2025-Financial-Results-and-Business-Update-on-November-10-2025.html

GLOBENEWSWIRE
05 Nov 2025

https://www.biospace.com/drug-development/skyes-cb1-inhibitor-shows-intriguing-synergy-with-wegovy-despite-mid-stage-obesity-fail

BIOSPACE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161581/0/en/Skye-Bioscience-Reports-Topline-CBeyond-Phase-2a-Data-from-Nimacimab-Monotherapy-and-Combination-Clinical-Trial.html

GLOBENEWSWIRE
06 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty